ArticleApplied biosafety : journal of the American Biological Safety Association2025
Governing Dual-Use Research of Concern in the Life Sciences: United States and Canada Policy Comparative Analysis and Recommendations.
Article in Applied biosafety : journal of the American Biological Safety Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study examines and compares dual-use research of concern (DURC) policies in the United States and Canada, two countries with advanced biosafety frameworks, to identify strengths, weaknesses, and areas for improvement in DURC governance. Methods: The study conducts a comprehensive review of current DURC policies, regulatory frameworks, and oversight mechanisms in the United States and Canada, analyzing key policy documents, including the 2024 U.S. Government Policy for Oversight of DURC and Canada's Human Pathogens and Toxins Act. Results: Both U.S. and Canadian DURC policies require principal investigators (PIs) to conduct continuous project reviews throughout the research duration and maintain dedicated advisory agencies for biosecurity. Their approaches are notably multi-layered, integrating policymaking with educational initiatives and surveillance systems. However, important differences exist in their governance strategies. The United States has specific DURC policies primarily for federally funded research, while Canadian regulations apply to all facilities handling human pathogens and toxins. Notably, Canada also employs more detailed pathogen classification and quantity specifications than the United States and requires designated biological safety officers for oversight. Conclusion: While both countries maintain robust DURC oversight frameworks, they differ in their approach to governance, scope, and implementation. Based on this analysis, five key recommendations were developed. This includes establishing an international minimum standard for DURC regulation, extending U.S. DURC legislation to non-federally funded research, developing detailed risk-benefit analysis guidelines, and strengthening policies for responsible scientific communication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.